Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 1019-6439 Online ISSN: 1791-2423
Journal Cover
March-2018 Volume 52 Issue 3

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March-2018 Volume 52 Issue 3

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis

  • Authors:
    • Hiroki Arai
    • Ryuichi Wada
    • Kousuke Ishino
    • Mitsuhiro Kudo
    • Eiji Uchida
    • Zenya Naito
  • View Affiliations / Copyright

    Affiliations: Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113-8602, Japan, Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo 113-8602, Japan
  • Pages: 978-988
    |
    Published online on: January 5, 2018
       https://doi.org/10.3892/ijo.2018.4238
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Gastric cancer is the third major cause of cancer-related mortality in Japan. The aim of this study was to identify a factor implicated in the biology of gastric cancer by comprehensive protein profiling. Protein profiling was carried out by liquid chromatography-tandem mass spectrometry, using formalin-fixed paraffin-embedded specimens of 17 gastric cancer cases. Pathway analysis and orthogonal partial least square-discriminant analysis suggested the significant expression of ribonucleoproteins, heterogeneous nuclear ribonucleoproteins, interleukin binding factor 2 (ILF2), KU70 and KU80, which are involved in DNA damage response (DDR). Thus, the expression and phosphorylation levels of KU70, ILF2, CHK1 and CHK2 were examined by immunohistochemistry in 42 cases of gastric cancer. The expressions of ILF2 and CHK1 were unaffected in all cases. The expression and phosphorylation of CHK2 were absent in 2 cases. Despite the expression of proteins, the phosphorylation of KU70 and CHK2 appeared to be impaired in 1 and 4 cases, respectively. In 7 out of 42 cases (17%), DDR appeared to be impaired. Recurrence was noted in 2 out of these 7 cases (29%), whereas the recurrence was noted in 2 out of the remaining 35 cases (6%). The expression levels of KU70, ILF2, CHK1, CHK2 and TP53 were further examined in 4 gastric cancer cell lines. The expression and phosphorylation levels following exposure to ultraviolet radiation were abnormal in the 3 cell lines. The normal consecutive phosphorylation of CHK1 and CHK2, the upregulation of TP53 and an increase in apoptotic cell death following exposure to ultraviolet radiation was detected only in one cell line, suggesting that the preserved functions of DDR and TP53 are necessary for the determination of cell fate. It is thus suggested that DDR plays an important role in the pathobiology of gastric cancers.

Introduction

Gastric cancer is the third major cause of the cancer-related mortality in Japan. Owing to endoscopic examination and surgery combined with chemotherapy, the prognosis of patients with gastric cancer has improved (1,2). However, there are still cases of gastric cancer which are diagnosed at an advanced stage, and in these cases, prognosis is unfavorable. To date, the factors that are involved in the pathogenesis and the progression of the gastric cancer have not yet been fully elucidated.

For the elucidation of the pathogenesis of the disease, the comprehensive profiling of proteins, DNA, RNA and metabolites has been carried out (3,4). This profiling would provide invaluable information useful for the identification of molecules of therapy, diagnosis and tumor biology. The comprehensive profiling of proteins and mRNAs has been carried out in gastric cancers (5–9). These molecular studies have revealed that gastric cancers are classified into 4 subtypes: The CpG island methylator phenotype, hypermutated, genomically stable and chromatin instability (6). These subtypes appear to represent the pathogenetic differences of gastric cancers. It is expected that the elucidation of the pathogenesis of gastric cancers leads to the development of specific treatment (8). Molecular information is required for the development of individualized therapy (2).

In the present study, the comprehensive protein profiling of gastric cancers was carried out using protein samples extracted from formalin-fixed paraffin-embedded (FFPE) specimens. Bioinformatics analyses suggested the significance of the expression of proteins in DNA damage response (DDR). DDR is the consecutive sequence from the detection of damaged DNA, the aggregation of transducers and modulators at the damaged site, cell cycle arrest and the repair of the damaged DNA. The rapid and uncontrolled progression of the cell cycle of carcinoma cells causes frequent errors in genome duplication, and the defect in DDR may enhance genetic instability and lead to the progression of carcinoma (10). In this study, the expression of molecules of DDR and the phosphorylation state of proteins were examined in cases of gastric cancer and in cultured gastric cancer cell lines. The preserved expression and phosphorylation of DDR proteins appeared to be associated with a favorable prognosis.

Materials and methods

Cases of human gastric cancer

Cases of gastric cancer were retrieved from the archives of the pathology records of Nippon Medical School Hospital (Tokyo, Japan) from 2011 to 2016. In total, 17 cases were used for the profiling of expressed proteins, and they were selected randomly from the pathology records. A total of 42 cases were used for the histological and immunohistochemical analyses. The cases were randomly selected from the cases of gastric cancer at pathological stages from I to III. The patients underwent gastrectomy, but they did not receive chemotherapy or radiation therapy prior to surgery. The study was conducted according to the declaration of Helsinki and the Japanese Society of Pathology. This study was approved by the Ethics Committee of Nippon Medical School Hospital (#29-06-764). Informed consent was obtained from all patients.

Comprehensive profiling of protein expression

FFPE specimens from 17 cases of gastric cancer were used for the comprehensive profiling of proteins by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The sections of gastric cancer (10-µm-thick) were deparaffinized in xylene and rehydrated through a graded alcohol series. Following staining with hematoxylin, the cancer tissues were dissected out under a stereoscopic microscope (AZ-STDM; Nikon Co., Tokyo, Japan) and lysed in buffer with 100 mM Tris-HCl (pH 9.0)/12 mM deoxycholate/12 mM lauroyl sarcosine. Following the quantification of the protein concentration by Bradford method using Bio-Rad Protein assay (Bio-Rad, Laboratories, Inc., Hercules, CA, USA), 10 µg of extracted protein was reduced in 11.4 mM dithiothreitol (DTT)/1.8 mM Tris (2-carboxyethyl) phosphine hydrochloride and alkylated in 54 mM iodoacetamide. It was further digested with proteomics-grade trypsin (Agilent Technologies Inc., Santa Clara, CA, USA) at 37°C for 24 h, and the protein was purified with a PepClean C-18 spin column (Thermo Fisher Scientific, K.K., Tokyo, Japan). In total, 2 µg of digested protein was injected into a Nano cHiPLC Trap column (0.2×0.5 mm, ChromXP C18-CL 3 µm) and further separated through a Eksigent nano LC Ekspert415 system using a reverse-phase C-18 column (0.075×150 mm, ChromXP C18-CL 3 µm) (all from K.K. Sciex Japan, Tokyo, Japan). The protein solution was run with the gradient concentration of acetonitrile from 2 to 32% in 0.1% formic acid in acetonitrile at a flow rate of 300 nl/min for 120 min. Eluted peptides were analyzed by Triple TOF 5600+ mass spectrometer (K.K. Sciex Japan). The data of 10 most intense peaks of each full MS scan were acquired. All MS/MS spectral data were analyzed by MASCOT 2.4 (Matrix Science K.K., Tokyo, Japan) with SwissProt 2015_02. The following parameter settings were used: Trypsin cleavage; two missed cleavage sites allowed for cysteine carbamidomethylation (C-terminus) and methionine oxidation (N-terminus). Peptide mass tolerance was set to ±50 ppm, and fragment MS/MS tolerance were set to 0.05 Da. The amounts of identified proteins were expressed as normalized spectral abundance factor (NSAF).

Bioinformatics analyses

Protein expression was analyzed by hierarchical clustering, orthogonal partial least squares-discriminant analysis (OPLS-DA) and Ingenuity Pathway Analysis (IPA). Analyses were done using NSAF of protein.

Hierarchical clustering was carried out using Cluster 3.0 and visualized using TreeView software (Howard Hughes Medical Institutes, University of California at Berkeley, Berkeley, CA, USA). Analysis with OPLS-DA was carried out using SIMCA version 14 (Umetrics, Umea, Sweden) to identify proteins which have a significant influence on the magnitude {p[1]} and reliability {p(corr)[1]} to separate into 2 clusters. The results were visualized as S-PLOT, a scatter plot with magnitude {p[1]} as the x-axis and reliability {p(corr)[1]} as the y-axis. The reliability, which was ≥0.6 and ≤−0.6 was considered significant. Pathways of expressed proteins were analyzed by IPA (Qiagen, Redwood City, CA, USA). The scores of networks were calculated by the numbers of focus proteins. The percentages of the number of reliable proteins evaluated by OPLS-DA in the number of focus proteins of each network identified by IPA were then calculated. It was expected that the combined analysis of OPLS-DA and IPA was useful to identify the biologically significant proteins from the profiled proteins.

Histological examination of human gastric cancers

A total of 42 cases of gastric cancer were used for the histological and immunohistochemical analyses. The histological subtypes were classified according to the classification by Lauren (11). Pathological T-factors, lymphovascular invasion and lymph node metastasis were also reviewed. The review of the histology was performed by 3 investigators (H.A., R.W. and Z.N.).

Immunohistochemistry

Immunohistochemistry was performed using the polymer-based two-step method. Briefly, the paraffin-embedded sections were deparaffinized and hydrated in phosphate-buffered saline (PBS). After the blocking of endogenous peroxidase, the sections were pretreated, if necessary, and then incubated with primary antibodies listed in Table I at 4°C overnight. The sections were then incubated with Simple Stain MAX-PO (R) for rabbit primary antibody or (M) for mouse primary antibody (Nichirei Inc., Tokyo, Japan). Peroxidase activity was visualized by diaminobenzidine.

Table I

The antibodies used in the present study.

Table I

The antibodies used in the present study.

AntibodyCloneSpeciesDilution WBIHCPTCompany/provider
KU70EPR4026Rabbit1:10,0001:2,000–Abcam K.K., Tokyo, Japan
p-KU70 (Ser5)ab61783Rabbit1:10,0001:2,000TBAbcam K.K., Tokyo, Japan
ILF2ab28772Rabbit1:1,000–CBAbcam K.K., Tokyo, Japan
CHK12G1D5Mouse1:1,0001:500TBCell Signaling Technology, Japan, K.K. Tokyo, Japan
p-CHK1 (Ser317)D92H3Rabbit1:1,0001:5,000CBCell Signaling Technology, Japan, K.K. Tokyo, Japan
CHK2D9C6Rabbit1:1,0001:1,000CBCell Signaling Technology, Japan, K.K. Tokyo, Japan
p-CHK2 (Thr68)C13C1Rabbit1:1,0001:1,000TBCell Signaling Technology, Japan, K.K. Tokyo, Japan
TP53DO7Mouse1:1,000–CBAgilent Technologies Japan, Ltd. Tokyo, Japan

[i] CB, citrate buffer (pH 6.0) at 121°C for 15 min; IHC, immunohistochemistry; PT, pretreatment; TB, Tris buffer (pH 9.0) at 121°C for 15 min; WB, western blot analysis. ILF2, interleukin binding factor 2.

Culture of gastric cancer cell lines and exposure to ultraviolet (UV) radiation

Four gastric cancer cell lines, NS-8, MKN-7, NUGC-4 and KATO-III, were used in this study. The cells were cultured in DMEM with 10% fetal bovine serum and penicillin/streptomycin. The cells were exposed to UV radiation at a dose of 40 J/m2. At 2 h following exposure, the cells were washed with PBS and lysed in 50 mM Tris-HCl (pH 7.6). The sample was then sonicated for 10 min.

Western blot analysis

The cell lysate was electrophoresed and blotted onto a polyvinylidene difluoride membrane. After the blocking in 5% skim milk in buffer of 0.2 M Tris-HCl (pH 7.6)/150 mM NaCl/0.01% Tween-20, the membrane was incubated with the primary antibodies listed in Table I overnight. The membrane was then incubated with peroxidase-labeled anti-mouse immunoglobulin antibody (#A106PU) or anti-rabbit immunoglobulin antibody (#A102PU) (both from American Qualex Scientific Products, San Clemente, CA, USA), and the peroxidase activity was detected as chemiluminescence using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, K.K.).

Analysis of apoptotic cell death in cultured cells

Cell death was examined using the Apoptosis, Necrosis and Healthy Cell Quantitation kit (Biotium, Inc., Hayward, CA, USA). Briefly, the cultured cells were washed with PBS, and incubated with a mixture of FITC-labeled Annexin V and Hoechst 33342 at room temperature for 15 min. Apoptosis was identified when cells were stained positive for FITC. The frequency of apoptotic cell death was calculated by dividing the number of apoptotic cells by the total number of cells. A total of at least total 500 cells was counted.

Statistical analysis

All quantitative data are expressed as the means ± SD. The distribution of cases was analyzed by the Chi-square test with Fisher's correction. The data of 2 groups were analyzed by the Mann-Whitney U test. P-values <0.05 was considered to indicate statistically significant differences. All statistical analyses were carried out using JMP 13.0 software (SAS Institute Japan, Ltd., Tokyo, Japan).

Results

Comprehensive profiling of protein expression and bioinformatics analyses

The comprehensive profiling of proteins was performed with the proteins purified from the FFPE samples of 17 cases of gastric cancer. A total of 5,338 proteins were identified by LC-MS/MS. NSAFs of housekeeping proteins, such as β-actin and histones were comparable among the cases (data not shown).

Among the 5,338 proteins, 483 proteins (9%) were expressed in all 17 cases. The other proteins were not detected at least one case. Unsupervised hierarchical clustering was performed with these 483 proteins (Fig. 1A). The gastric cancers were separated into 2 major clusters. The left cluster included 9 cases, and the right cluster included 8 cases. There was no significant difference as regards age, location, pathological T factor and pathological stage between the 2 clusters (Table II). All cases in the right cluster were male. The intestinal subtype was predominant in the left cluster, whereas the diffuse subtype was predominant in the right cluster.

Figure 1

Comprehensive analysis of expressed proteins. (A) Hierarchical cluster analysis of protein expression in gastric cancer. The cases of gastric cancers were separated into 2 major clusters. (B) S-PLOT of magnitude (p[1]) and reliability {p(corr)[1]} of proteins analyzed by orthogonal partial least squares-discriminant analysis.

Table II

Clinicopathological characteristics of the patients with gastric cancer in the left and right clusters.

Table II

Clinicopathological characteristics of the patients with gastric cancer in the left and right clusters.

Left cluster (n=9)Right cluster (n=8)P-value
Age (years)72±1274±7ns
Sex
 Male48P<0.05
 Female50
Location
 Upper41ns
 Middle11
 ML12
 Lower34
Lauren classification
 Intestinal62P<0.05
 Mixed31
 Diffuse05
pT
 pT165ns
 pT213
 pT320
 pT400
Stage
 I65ns
 II23
 III10
 IV00

[i] ML, middle to lower; ns, not significant.

To identify the proteins reliable to separate the left and right clusters, OPLS-DA was carried out with NSAF of 483 proteins and visualized by S-PLOT (Fig. 1B). The reliability {p(corr)[1]} of 33 proteins was ≥0.6, and it was considered that they had significant reliability to discriminate the right cluster (Table III). On the other hand, the reliability of 46 proteins was ≤−0.6, and they had significant reliability for the discrimination of the left cluster (Table IV).

Table III

Proteins identified by orthogonal partial least squares-discriminant analysis (the reliability is ≥0.6).

Table III

Proteins identified by orthogonal partial least squares-discriminant analysis (the reliability is ≥0.6).

ProteinMagnitude p[1]Reliability p(corr)[1]
INA0.0550520.909151
ACTA20.2469020.897744
ACTC10.2457030.896767
ACTA10.2307180.884632
VIM0.2057290.880668
ACTB0.2382750.878102
ACTBL20.1780690.820505
PRPH0.0585220.808254
TPM10.1168850.797396
TPM20.1219690.797050
FLNA0.0780550.768442
TPM30.0930250.762556
CSRP10.0556340.761816
TAGLN0.1856550.745214
FLNC0.0272180.735016
FTL0.1039660.726628
ANXA60.0718630.724106
ANXA50.0951320.710682
MSN0.0508980.695238
DES0.1377570.684517
S100A40.0593890.682374
MYH100.0376590.667677
MYL60.0878130.664537
POTEKP0.1262130.664068
POTEE0.0767390.660707
RDX0.0324700.649216
PKLR0.0241080.646927
COL6A30.0804830.634928
COL6A20.0756060.632119
COL6A10.0729510.624386
LUM0.0877450.619709
POTEI0.0437630.616854
VCL0.0480170.610764

Table IV

Proteins identified by orthogonal partial least squares-discriminant analysis (the reliability is ≤−0.6).

Table IV

Proteins identified by orthogonal partial least squares-discriminant analysis (the reliability is ≤−0.6).

ProteinMagnitude p[1]Reliability p(corr)[1]
HYOU1−0.031015−0.600712
NME1−0.085839−0.601319
RPS16−0.063733−0.606282
ATIC−0.033951−0.609055
HNRNPA1L2−0.045016−0.610854
ETFB−0.047257−0.611190
PDLIM1−0.034208−0.612325
RNPEP−0.032576−0.612375
CUTA−0.032975−0.624701
RPS5−0.038159−0.635456
RPSA−0.056624−0.640193
RPS13−0.061149−0.641738
XRCC5−0.035668−0.643890
HNRNPC−0.052836−0.649307
RPS19−0.061370−0.653405
TXN−0.099468−0.654578
SFPQ−0.030426−0.656324
RPL4−0.036438−0.660385
HNRNPU−0.036768−0.661809
RPS18−0.066594−0.662418
PSMA6−0.052565−0.663324
EEF1B2−0.043041−0.663354
PHB−0.065979−0.667600
C1QBP−0.062352−0.669720
DDX3X−0.028476−0.670196
HSPD1−0.071720−0.670892
PABPC1−0.034400−0.690058
HSD17B10−0.054045−0.691120
NANS−0.031787−0.693264
PDCD6−0.061551−0.693424
HNRNPM−0.034036−0.699508
SYNCRIP−0.039143−0.699748
AKR1A1−0.064921−0.700549
CTNND1−0.023981−0.701687
HNRNPH1−0.044206−0.731575
XRCC6−0.059573−0.739444
RPS4X−0.055168−0.739747
RPS23−0.037777−0.745383
CCT2−0.057704−0.755868
ETHE1−0.069280−0.765860
ILF2−0.054563−0.777686
CIRBP−0.041115−0.785409
HNRNPF−0.050593−0.787704
EEF2−0.052731−0.800286
VCP−0.062993−0.809144
RPS7−0.080280−0.826483

Networks of proteins were analyzed by IPA with NSAF of 483 proteins, and a total of 24 networks was identified. To identify proteins which are biologically significant in gastric cancer, protein expression was further analyzed by combining the results of OPLS-DA and IPA. The proteins identified as reliable for the discrimination of right clusters were enriched in networks 2 and 19 (Table V). The percentages of proteins identified by OPLS-DA (double underlined proteins in Table V) in the focus molecules of network 2 and 19 were 23% (7/31) and 54% (7/13), respectively. They were intermediate filaments, matrix proteins and their binding proteins. Some were associated with cell death. The combined networks of 2 and 19 are shown in Fig. 2A. Among the 322 connections, 53 connections (pink-colored lines in Fig. 2A, 17%) were interactions between the proteins in 2 networks. On the other hand, the proteins identified as reliable for the discrimination of the left cluster by OPLS-DA were enriched in networks 1, 3, 5 and 9 (Table V). The percentages of proteins identified by OPLS-DA (underlined proteins in Table V) in the focus molecules of networks 1, 3, 5 and 9 were 27% (9/33), 29% (8/28), 15% (4/27) and 16% (4/25), respectively. Combined networks formed tight connections (Fig. 2B), and 231 pink-colored connections out of 557 connections (42%) were interactions among 4 networks. The focus molecules were tightly linked, suggesting the close functional associations among the proteins (Fig. 2B). The majority of these proteins were ribosomal proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). The networks also included XRCC5 (KU80), XRCC6 (KU70) and interleukin enhancer binding protein 2 (ILF2).

Figure 2

Ingenuity Pathway Analysis of the proteins in gastric cancer. (A) Combined networks of 2 and 19. These networks were enriched with the proteins reliable to separate the right cluster. In total 53 (pink-colored) out of a total of 322 connections (17%) represent the interactions between the focus molecules in 2 networks. (B) Combined networks of 1, 3, 5 and 9. They were enriched with the proteins reliable to separate the left cluster. Out of the total 557 connections, 231 connections (pink-colored, 42%) represent the interactions among the focus molecules in 4 networks.

Table V

Networks identified by Ingenuity Pathway Analysis.

Table V

Networks identified by Ingenuity Pathway Analysis.

IDMolecules in networkScoreFocus moleculesTop diseases and functions
160S ribosomal subunit, CAND1, CIRBP, EEF1A2, EEF1G, EIF3A, HNRNPA1L2, HNRNPCL1/HNRNPCL2, HNRNPDL, HNRNPK, HNRNPR, HNRNPU, KRT76, PABPC1, PCBP1, PCBP2, Ras, RPL4, RPL14, RPL38, RPLP0, RPS3, RPS8, RPS9, RPS10, RPS16, RPS19, RPS25, RPSA, SND1, SRSF3, SRSF7, SYNCRIP, TARDBP, UBA525733RNA post-transcriptional modification, protein synthesis, Cancer
2ACTB, ACTN1, ACTN4, ACTR3, ANXA6, ARPC2, ARPC4, ARPC5L, CALML3, CAPZA1, CAPZB, CLIC1, CLTCL1, CPNE1, EFHD2, ERK, FLNA, FLNB, GSN, IQGAP1, MYH9, MYH10, MYH11, MYL6, MYL12A, PLEC, PRDX4, Rlc, S100, S100A6, SPTAN1, SPTBN1, TMSB4, TPM2, TPM35231Cellular assembly and organization, xellular function and maintenance, cell-to-cell signaling and interaction
3ARCN1, Arf, ARF1, ARF4, ARF5, ATIC, COPI, COPA, COPB2, COPG1, ECHS1, EIF4A1, Eif4g, H2AFV, HNRNPA3, HNRNPH1, NPM1, nuclear factor 1, Pka, PKLR, PPA1, RAB13, ribosomal 40s subunit, Rnr, RPS5, RPS7, RPS13, RPS18, RPS20, RPS23, RPS26, RPS28, RPS15A, RPS4X, UBA14428Cancer, cell death and survival, organismal injury and abnormalities
5ACAA2, adaptor protein 1, AKR1A1, alcohol dehydrogenase, aldo, ALDOA, ALDOC, ANXA11, COL6A1, CPNE2, EGLN, ENO2, ENO3, enolase, ETFA, ETFB, GAPDH, HSD17B10, IDH1, IDH2, IGHG2, Jnk, PDCD6, PGAM1, PGAM2, Pgk, PGK1, PGK2, PTRF, PYGB, PYGL, SEPT2, SEPT9, TPI1, transglutaminase4227Cancer, cell death and survival, organismal injury and abnormalities
914-3-3 (β,ε,ζ), 14-3-3 (β,γ,θ,η,ζ), 14-3-3 (η,θ,ζ), AHNAK, H2AFY, BLVRB, DHX9, dishevelled, glycogen synthase, Gsk3, HIST1H2BA, HIST1H2BB, HIST2H2AB, HNRNPA2B1, HNRNPC, ILF2, NCL, PP1-C, RPA, RPL6, RPL12, RPL31, RPLP1, RPLP2, S100A10, snRNP, SNRPB, SNRPD3, SRSF1, Top2, WARS, XRCC5, XRCC6, YWHAE, YWHAQ3725RNA post-transcriptional modification, cell morphology, cellular function and maintenance
19ACTA2, α catenin, ANXA5, atypical protein kinase C, COL6A2, COL6A3, collagen, collagen α1, collagen type I, collagen type II, collagen type III, collagen type IV, collagen(s), Cpla2, focal adhesion kinase, GNA12, growth hormone, Hsp27, ITGB1, laminin, laminin1, LUM, Pdgf, PDGF BB, Pkg, Pld, POSTN, RAP1A, SERPINH1, Smad2/3, Sos, TAGLN, Tgfβ, TPP1, VIM1413Developmental disorder, organismal injury and abnormalities, connective tissue disorders

[i] The proteins shown in bold are focus molecules. The underlined text indicates that the reliability {p(corr)[1]} evaluated by the orthogonal partial least square-discriminant analysis is <−0.6, and the double underlined text indicates that the reliability is >0.6.

KU70 and KU80 are sensors of damaged DNA (12). ILF2 regulates the splicing of mRNAs, and it has been shown that ILF2 regulates RNA processing of genes involved in DDR (13). hnRNPs and ribosomal proteins stabilize mRNAs and regulate the splicing and translation of mRNAs, and it was recently shown that hnRNPs and ribosomal proteins stabilize the genome when DNA is damaged (14). The tight connections of these proteins raise the possibility of the involvement of DDR in gastric cancer. DDR is exerted by the orchestration of molecules, sensors of damaged DNA, transducers, mediators and effectors to repair the damaged DNA and to determine the fate of the cell (Fig. 3). The transduction pathway is exerted by the phosphorylation of proteins. Thus, in this study, the expression and phosphorylation of key proteins of DDR were examined by immunostaining of 42 cases of gastric cancer.

Figure 3

Overview of pathway of DNA damage response. The pathway consists of sensors of damaged DNA, transducers, mediators and effectors to decide the cell fate. Heterogeneous nuclear ribonucleoproteins stabilize the damaged DNA. The schema is modified from previous studies (12,14).

Clinicopathological characteristics and DNA damage response proteins in gastric cancers

The clinicopathological characteristics of 42 cases of gastric cancer are summarized in Table VI. The age of the patients varied from 53 to 86 years. In total, 35 cases were male, and 7 cases were female. Histological subtypes were evaluated by Lauren classification, and the number of cases of intestinal, diffuse and mixed types were 20 (48%), 12 (29%) and 10 (23%) cases, respectively (Table VI).

Table VI

Clinicopathological characteristics and immunohistochemical results of the cases of gastric cancer.

Table VI

Clinicopathological characteristics and immunohistochemical results of the cases of gastric cancer.

NoAge/sexLaurenpTpNStageKU70pKU70CHK1pCHK1CHK2pCHK2RecPrognosis
153/MIntestinal1a0IA++++++
255/MIntestinal31IIB++++++
356/MIntestinal1b10IIA++++++
459/MDiffuse4a0IIB++++++
562/MIntestinal4a3bIIIB+++++++, 3 moDOD, 18 mo
662/MIntestinal4a2IIIB++++++
763/MIntestinal32IIIA+++++++, 10 moDOD, 33 mo
864/MDiffuse33bIIIC++++++
965/MMixed4a1IIIA++++++
1065/MIntestinal1b21IB++++++
1165/MIntestinal1a0IA++++++
1266/MDiffuse20IB++++++
1368/MMixed1b20IA++++++
1468/MIntestinal1a0IA++++++
1570/MMixed23aIIIA++++++
1670/MMixed4a3aIIIC++++++
1770/MIntestinal31IIB++++++
1870/MMixed4a0IIB++++++
1970/MIntestinal21IIA++++++
2070/MIntestinal20IB++++++
2170/FIntestinal1a0IA++++++
2271/MIntestinal1b10IA++++++
2371/MDiffuse4a3bIIIC++++−−+, 4 moDOD, 5 mo
2473/FMixed30IIA+++++−
2574/MMixed32IIB+++++−
2674/MIntestinal20IB++++++
2775/MDiffuse21IIB++++++
2875/FDiffuse33aIIIB++++++
2976/MIntestinal1b10IA++++++
3076/MDiffuse1b20IA++++++
3176/MDiffuse20IB++++++
3276/FIntestinal20IB++++++
3377/MMixed4a3aIIIC++++−−DOOD
3478/MDiffuse1a0IA+−++++
3581/MIntestinal1b20IA++++++DOOD
3681/MDiffuse31IIB++++++
3781/MDiffuse1b22IIA++++++
3882/FMixed1b20IA++++++
3983/FMixed32IIIB+++++−+, 6 moDOD, 12 mo
4085/MIntestinal1b10IA++++++
4186/MDiffuse21IIA+++++−
4286/FIntestinal1a0IA++++++

[i] DOD, died of disease; DOOD, died of other disease; F, female; M, male; mo, month; Rec, recurrence.

Immunohistochemistry was performed using antibodies against KU70, pKU70, CHK1, pCHK1, CHK2 and pCHK2 (Fig. 4). The expression of KU70 was found in all cases, however, the phosphorylation was not apparent in one case (case 34) (Fig. 4 and Table VI). The expression of CHK1 and protein phosphorylation was observed in all cases. In 4 cases (cases 24, 25, 39 and 41) (Fig. 4 and Table VI), the expression of CHK2 was found in tumor cells; however, the positive reaction of pCHK2 was not apparent in tumor cells. The expression of CHK2 was not found in 2 cases (cases 23 and 33) (Fig. 4 and Table VI), and pCHK2 was also absent. The expression and phosphorylation of proteins of the DDR pathway appeared to be impaired in 7 (cases 23, 24, 25, 33, 34, 39 and 41) out of the 42 cases (17%) (Table VI).

Figure 4

Immunohistochemistry of proteins involved in the DNA damage response pathway in 42 cases of gastric cancers. The representative positive immunostaining images of gastric cancer are shown in the left panels (case 10). The representative immunostaining results of cases, which was negative for pKU70 (case 34), for pCHK2 (case 41), and for both CHK2 and pCHK2 (case 33).

Recurrence was noted in 2 out of 7 cases (29%), in which expression and phosphorylation were impaired (cases 23 and 39) (Table VI). One patient succumbed to the disease. On the other hand, out of remaining 35 cases, in which the DDR pathway was intact, recurrence was noted in 2 cases (6%, cases 5 and 7) (Table VI).

DNA damage response proteins and apoptotic cell death in gastric cancer cell lines

KU70 was expressed in all the cell lines apart from the NS-8 cells (Fig. 5). The differences in the expression levels of KU70 were not evident among the other cells. The expression of ILF2 was observed in all cell lines; however, the expression appeared to be decreased in the NS-8 cells. The expression level of CHK1 appeared similar among the cultured cells. CHK2 was overexpressed in the NS-8 cell; however, its molecular size differed from that observed in the other cell lines. The expression of TP53 was not detected in the NS-8 and KATO-III cells. TP53 was overexpressed in the MKN-7 cells, in which the TP53 gene is mutated (15).

Figure 5

The expression and phosphorylation of DNA damage response proteins in cultured gastric cancer cell lines. The proteins were extracted from cells not exposed to ultraviolet radiation (−) or those exposed to ultraviolet radiation (+) at 2 h after the exposure. The expression of KU70 was absent, and that of interleukin binding factor 2 (ILF2) was decreased in the NS-8 cells. The aberrant overexpression of CHK2 was also noted in the NS-8 cells. The aberrant expression TP53 was observed in the NS-8, MKN-7 and KATO-III cells.

At 2 h following exposure to UV radiation, the expression level of KU70 appeared to be unaltered, and its phosphorylation was not evident after 2 h (Fig. 5). The phosphorylation of CHK1 was increased following exposure to UV radiation in cell lines; however, this increase was not evident in the NS-8 cells. The expression level of CHK2 remained unaltered following exposure to UV radiation, and CHK2 was phosphorylated in the cultured cells apart from the NS-8 cells. Overexpressed TP53 in the MKN-7 remained unaltered following exposure to UV radiation. In the NUGC-4 cells, the expression of TP53 was upregulated at 2 h following exposure to UV radiation.

Morphologically, some cultured cells appeared to be swollen at 2 h following exposure to UV radiation (Fig. 6A). The amount of apoptotic cells was increased following exposure to UV radiation in all cell lines apart from the KATO-III cells. The increase in apoptotic cell death following exposure to UV radiation appeared to be pronounced in the NUGC-4 cells, although the difference did not reach statistical significance (Fig. 6B).

Figure 6

Morphological changes and apoptotic cell death in gastric cancer cell lines not exposed to ultraviolet (UV−) and those exposed to ultraviolet (UV+) at 2 h after the exposure. (A) Some cells appeared to be swollen following exposure to ultraviolet radiation. Apoptotic cells were identified by membranous staining with Annexin V (green color). The cells were counterstained with Hoechst 33342 (blue). (B) Frequency of apoptotic cell death in cultured cell lines. The data represent the means ± SD. Apoptotic cell death following exposure to ultraviolet radiation was increased in the NUGC-4 cells.

Discussion

The present study revealed the biological and clinical significance of DDR in gastric cancer. The comprehensive protein profiling and bioinformatics analyses suggested the possible involvement of DDR in gastric cancer. The expression and phosphorylation of the proteins of DDR were verified and examined in 42 cases of gastric cancer. Among these cases, the expression and phosphorylation of proteins of DDR appeared abnormal in 7 out of 42 cases (17%). Although the number of cases was limited, the recurrence in the cases with an impaired expression and the phosphorylation of DDR proteins was more frequent than that in cases with a preserved expression and phosphorylation of the proteins. In the cultured gastric cancer cells, the effective induction of apoptotic cell death following exposure to UV radiation was observed in one cell line with a preserved expression and phosphorylation of DDR proteins.

The comprehensive profiling of molecules in gastric cancers has been reported in the literature (5,6,16). It was indicated that gastric cancers are categorized into 4 subtypes, CpG island methylator phenotype, hypermutated, genomically stable and chromatin instability (6). However, definitive molecular alterations, which are involved in pathogenesis and progression of gastric cancer, have not been identified. In the present study, for the identification of molecules or pathway commonly involved in the pathobiology of gastric cancer, the proteins that were expressed in all 17 cases gastric cancer were analyzed. The number of these proteins constituted 9% (483/5,338) of the total proteins identified by LC-MS/MS, and the proteins with a subtle expression, as well as proteins expressed specifically in certain subtypes of gastric cancer may have been excluded from the analyses. This analytical strategy may pronounce the alterations of proteins commonly expressed in gastric cancer.

DDR has been implicated in the tumorigenesis and progression of human cancers (17–19). The impairment of DDR causes the genetic instability of the cell. DDR may serve not only as a barrier to neoplastic cells, but also as a barrier of the progression of neoplastic cells to highly malignant cells (17). The biological significance of DDR in gastric cancer has not yet been fully elucidated. It was previously reported that the expression level of CHK2 was increased in cases with a mutation of the TP53 gene. The expression level of CHK1 was also increased in gastric cancers; however, there was no significant correlation between the expression level of CHK1 and the mutational state of TP53 (20). It has also been demonstrated that the loss of ATM and CHK2 is 17.3 and 12.2% in gastric cancers (21). The percentage of the absence of the expression and/or phosphorylation of CHK2 in gastric cancer in the present study was in agreement with these findings, and its expression and/or phosphorylation were not noted in 6 cases out of the 42 cases (14.3%). Furthermore, the phosphorylation of KU70 appeared to be impaired in one case by immunostaining in the present study.

The impairment of DDR may affect the prognosis of gastric cancer. It has been reported that patients with a positive expression of ATM, CHK2 and TP53 present with a favorable prognosis, and the loss of CHK2 is associated with the reduction of ATM, and/or TP53 is an independent factor for a poor prognosis (21). In the present study, recurrence was noted in 2 out of 7 cases (29%), in which the expression and phosphorylation of DDR-related proteins were impaired, whereas recurrence was noted in 2 out of 35 cases (6%), in which the expression and phosphorylation DDR were intact. The impairment of DDR appeared to be associated with an unfavorable prognosis. The follow-up duration, and the number of cases was limited in the present study. Further studies are warranted in order to clarify the prognostic significance of DDR.

The aberrant expression of DDR proteins was noted in cultured gastric cancer cell lines. The expression of KU70, ILF2 and CHK2 was aberrant in one cell line, the NS-8 cells, which has characteristic features of the amplification of the N-ras gene and the production of α-fetoprotein (22). The consecutive alteration of the expression and phosphorylation of DDR protein following exposure to UV radiation were further examined, and the phosphorylation of CHK1 and CHK2 was decreased in NS-8. The upregulation of TP53 following exposure to UV radiation was noted in only one cell line, NUGC-4, and the increase in apoptotic cell death was evident only in this cell line. It is thus considered that the preservation of DDR and the TP53 response are necessary for the determination of cell fate and the induction of apoptosis. This may in part account for the favorable outcome in patients with gastric cancer with a preserved expression of DDR proteins (21).

DDR may affect the susceptibility to chemotherapy in gastric cancer. The expression of XRCC1 is increased in cisplatin-resistant cancer cells (23). In cases of gastric cancer, the elevated expression of γH2AX and pATM is adverse for progression-free and overall survival (24). In addition, the targeting of CHK2 enhances cell death by treatment with cisplatin and paclitaxel in cultured cell lines (25). It thus appears that the expression of DDR proteins attenuates the susceptibility to chemotherapy, although this may be affected by other genetic factors, such as ARID1A (24). The association of DDR with the efficacy of chemotherapy needs to be elucidated.

Glossary

Abbreviations

Abbreviations:

DDR

DNA damage response

ILF2

interleukin binding factor 2

hnRNPs

heterogeneous nuclear ribonucleoproteins

FFPE

formalin-fixed paraffin-embedded

IPA

Ingenuity Pathway Analysis

LC-MS/MS

liquid chromatography-tandem mass spectrometry

NSAF

normalized spectral abundance factor

OPLS-DA

orthogonal partial least squares discriminant analysis

PBS

phosphate-buffered saline

TBS

Tris-buffered saline

TUNEL

terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling

UV

ultraviolet

XRCC

X-ray repair cross complementing

Acknowledgments

The authors would like to thank Ms. Kiyoko Kawahara, Mr. Takenori Fujii, Mr. Kiyoshi Teduka, Ms. Yoko Kawamoto and Ms. Taeko Kitamura for their assistance with this manuscript.

Notes

[1] Competing interests

The authors declare that they have no competing interests.

References

1 

Kodera Y: The current state of stomach cancer surgery in the world. Jpn J Clin Oncol. 46:1062–1071. 2016. View Article : Google Scholar

2 

Shitara K: Chemotherapy for advanced gastric cancer: Future perspective in Japan. Gastric Cancer. 20(Suppl 1): 102–110. 2017. View Article : Google Scholar

3 

Eke I, Makinde AY, Aryankalayil MJ, Ahmed MM and Coleman CN: Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett. 382:118–126. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Pan L, Aguilar HA, Wang L, Iliuk A and Tao WA: Three-dimensionally functionalized reverse phase glycoprotein array for cancer biomarker discovery and validation. J Am Chem Soc. 138:15311–15314. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, Taupin D, Gorringe K, Haviv I, Desmond PV, et al: Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 63:2569–2577. 2003.PubMed/NCBI

6 

Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, et al Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar :

7 

Sousa JF, Ham AJ, Whitwell C, Nam KT, Lee HJ, Yang HK, Kim WH, Zhang B, Li M, LaFleur B, et al: Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol. 181:1560–1572. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Sunakawa Y and Lenz HJ: Molecular classification of gastric adenocarcinoma: Translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 16:172015. View Article : Google Scholar : PubMed/NCBI

9 

Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 141:476–485. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature. 461:1071–1078. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI

12 

Blanpain C, Mohrin M, Sotiropoulou PA and Passegué E: DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell. 8:16–29. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, et al: ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 32:88–100. e1062017. View Article : Google Scholar : PubMed/NCBI

14 

Kai M: Roles of RNA-binding proteins in DNA damage response. Int J Mol Sci. 17:3102016. View Article : Google Scholar : PubMed/NCBI

15 

Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int. 50:767–777. 2000. View Article : Google Scholar : PubMed/NCBI

16 

Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI

18 

Halazonetis TD, Gorgoulis VG and Bartek J: An oncogene-induced DNA damage model for cancer development. Science. 319:1352–1355. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Poehlmann A and Roessner A: Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract. 206:591–601. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Shigeishi H, Yokozaki H, Oue N, Kuniyasu H, Kondo T, Ishikawa T and Yasui W: Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations. Int J Cancer. 99:58–62. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Lee HE, Han N, Kim MA, Lee HS, Yang HK, Lee BL and Kim WH: DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. Pathobiology. 81:25–35. 2014. View Article : Google Scholar

22 

Matsunobu T, Ishiwata T, Yoshino M, Watanabe M, Kudo M, Matsumoto K, Tokunaga A, Tajiri T and Naito Z: Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. Int J Oncol. 28:307–314. 2006.PubMed/NCBI

23 

Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X, Zhang J, Qiang F, Li A, Røe OD, et al: TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis. 5:e10552014. View Article : Google Scholar : PubMed/NCBI

24 

Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, et al: DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Int J Cancer. 140:2587–2595. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Gutiérrez-González A, Belda-Iniesta C, Bargiela-Iparraguirre J, Dominguez G, García Alfonso P, Perona R and Sanchez-Perez I: Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis. 18:347–360. 2013. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Arai H, Wada R, Ishino K, Kudo M, Uchida E and Naito Z: Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis. Int J Oncol 52: 978-988, 2018.
APA
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., & Naito, Z. (2018). Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis. International Journal of Oncology, 52, 978-988. https://doi.org/10.3892/ijo.2018.4238
MLA
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., Naito, Z."Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis". International Journal of Oncology 52.3 (2018): 978-988.
Chicago
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., Naito, Z."Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis". International Journal of Oncology 52, no. 3 (2018): 978-988. https://doi.org/10.3892/ijo.2018.4238
Copy and paste a formatted citation
x
Spandidos Publications style
Arai H, Wada R, Ishino K, Kudo M, Uchida E and Naito Z: Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis. Int J Oncol 52: 978-988, 2018.
APA
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., & Naito, Z. (2018). Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis. International Journal of Oncology, 52, 978-988. https://doi.org/10.3892/ijo.2018.4238
MLA
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., Naito, Z."Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis". International Journal of Oncology 52.3 (2018): 978-988.
Chicago
Arai, H., Wada, R., Ishino, K., Kudo, M., Uchida, E., Naito, Z."Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis". International Journal of Oncology 52, no. 3 (2018): 978-988. https://doi.org/10.3892/ijo.2018.4238
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team